he USA-India Chamber of Commerce (USAIC), a bilateral chamber of commerce, will organize its annual US-India BioPharma & Healthcare Summit on May 11, 2012, at the Hyatt Cambridge, Massachusetts, USA.
The summit will focus on overcoming the barriers in building collaborative partnerships between the Indian and global companies. Panel discussions and keynotes will cover Drug Discovery & Development, Emerging Markets, Licensing, Industry-Academic Partnerships, Clinical Research, Funding Innovation and Cross Border M&A trends. There will be a specific high powered panel discussion on oncology deliberating the science, research trends and investor perspective.
Exclusive invitation-only strategy sessions will focus on industry-academia partnerships, co-chaired by Noble Laureate Philip Sharp of MIT, and Dr Sridaran Natesan of Sanofi. External R&D strategies session will be co-chaired by Dr Rick Connell of Pfizer, Dr Sandeep Gupta of Endo Pharma and Sri Mosur of Jubilant Life Sciences.
Dr Elias Zerhouni, president Global R&D, Sanofi; Dr John Leonard, senior vice president R&D, Abbott; Dr Bill Hait, head of R&D, Johnson & Johnson Pharma; Dr Ivan Gergel, executive vice president, R&D, Endo Pharma; Dr Michael Rosenblatt, executive vice president & CMO, Merck; Dr George Scangos, CEO, Biogen Idec; Dr Roger Glass, director, Fogarty International Center (NIH); and Dr Peter Mueller, global head of R&D, Vertex Pharmaceuticals, will participate in the event.
The agenda for 2012 summit is a result of post summit strategy session held in Delhi in November 2011. The brainstorming session was attended by over 40 prominent CEOs, secretary biotechnology, secretary S&T, the DCGI and several joint secretaries.
USA-India Chamber of Commerce has an advisory board of key global R&D leaders, academicians and venture capitalists who are passionate about innovation in biopharma and healthcare. Annual R&D budget of the board members is more than $25 billion.